CureVac Establishes U.S. Operations in Cambridge, MA

11-Sep-2015 - Germany

CureVac announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technologyand multiple, clinical-stage mRNA therapeutics and vaccines.

The expansion into the U.S. extends the company’s footprint into one of the world’s preeminent biotechnology hubs. The US subsidiary will be headed by Karen Slobod, MD,as managing director, formerly Head of the Maternal Immunization Franchise at NovartisVaccines, and will primarily focus on development activities involving CureVac’s rapidly growing pipeline of mRNA-based prophylactic vaccines, which include programs targeting Rotavirus, RSV, HIV, and influenzavirusin collaborations with the Bill & Melinda Gates Foundation, IAVI and Johnson & Johnson. Additionally, the U.S. operations will enable CureVac to more directly engage the U.S. pharmaceutical and investor communities.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance